893 related articles for article (PubMed ID: 325806)
1. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
2. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
3. The natural modulation of the amplification phase of complement activation.
Fearon DT; Daha MR; Weiler JM; Austen KF
Transplant Rev; 1976; 32():12-25. PubMed ID: 62426
[TBL] [Abstract][Full Text] [Related]
4. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
5. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
6. Control of the amplification convertase of complement by the plasma protein beta1H.
Weiler JM; Daha MR; Austen KF; Fearon DT
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
[TBL] [Abstract][Full Text] [Related]
7. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
8. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
9. Initiation of C3 cleavage in the alternative complement pathway.
Fearon DT; Austen KF
J Immunol; 1975 Nov; 115(5):1357-61. PubMed ID: 809512
[TBL] [Abstract][Full Text] [Related]
10. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
Daha MR; van Es LA
J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
12. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
13. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
14. A molecular basis of activation of the alternative pathway of human complement.
Austen KF; Fearon DT
Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
[TBL] [Abstract][Full Text] [Related]
15. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
16. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
Gigli I; Sorvillo J; Halbwachs-Mecarelli L
J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
[TBL] [Abstract][Full Text] [Related]
17. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
18. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
20. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
Baker PJ; Adler S; Yang Y; Couser WG
J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]